Annual Reports

 
Quarterly Reports

  • 10-Q (Nov 6, 2014)
  • 10-Q (Aug 8, 2014)
  • 10-Q (May 9, 2014)
  • 10-Q (Nov 7, 2013)
  • 10-Q (Aug 9, 2013)
  • 10-Q (Jul 26, 2013)

 
8-K

 
Other

Alnylam Pharmaceuticals 10-Q 2011
exv12
Exhibit 12
STATEMENT REGARDING COMPUTATION OF CONSOLIDATED RATIOS OF EARNINGS/DEFICIENCIES TO FIXED CHARGES
(dollars in thousands)
                                                         
    Nine Months Ended     Three Months Ended        
    September 30,     September 30,     Fiscal Year Ended December 31,  
    2011     2011     2010     2009     2008     2007     2006  
Earnings (loss):
                                                       
Pre-tax loss from continuing operations before adjustment for loss from equity investee
  $ (40,795 )   $ (12,770 )   $ (35,362 )   $ (42,098 )   $ (16,240 )   $ (79,146 )   $ (34,608 )
add: Fixed charges (see below)
    905       302       1,207       712       1,115       1,553       1,532  
 
                                         
Pre-tax income (loss) from continuing operations before adjustment for income/loss from equity investees plus fixed charges
  $ (39,890 )   $ (12,468 )   $ (34,155 )   $ (41,386 )   $ (15,125 )   $ (77,593 )   $ (33,076 )
 
                                                       
Fixed charges:
                                                       
Interest expense on indebtedness
  $     $     $     $     $ 872     $ 1,083     $ 1,029  
Interest expense on portion of rent expense representative of interest
    905       302       1,207       712       243       470       503  
 
                                         
Total fixed charges
  $ 905     $ 302     $ 1,207     $ 712     $ 1,115     $ 1,553     $ 1,532  
 
                                         
 
                                                       
Ratio of earnings to fixed charges
                                         
 
                                         
 
                                                       
Deficiency of earnings available to cover fixed charges
  $ (40,795 )   $ (12,770 )   $ (35,362 )   $ (42,098 )   $ (16,240 )   $ (79,146 )   $ (34,608 )
 
                                         

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki